Text Size
18 studies found for:    pleural plaque OR pleural effusion OR asbestosis OR mesothelioma | Open Studies | NIH, U.S. Fed

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
pleural plaque OR pleural effusion OR asbestosis OR mesothelioma | Open Studies | NIH, U.S. Fed
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Pentostatin;   Drug: Cyclophosphamide;   Drug: SS1P
2 Recruiting Tivantinib in Treating Patients With Previously Treated Metastatic or Recurrent Malignant Mesothelioma
Conditions: Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Drug: tivantinib;   Other: laboratory biomarker analysis
3 Recruiting Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: pemetrexed disodium;   Drug: cisplatin;   Drug: cediranib maleate;   Other: placebo
4 Recruiting Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Conditions: Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Thymoma;   Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562);   Drug: Celecoxib;   Drug: cyclophosphamide
5 Recruiting Tumor Cell Vaccines With ISCOMATRIX(Trademark) Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Conditions: Mesolthelioma;   Esophageal Cancer;   Lung Cancer
Interventions: Drug: Celecoxib;   Drug: ISCOMATRIX (TM) Adjuvant;   Biological: Autologous Tumor Cell Vaccine
6 Recruiting Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Recurrent Malignant Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis;   Procedure: single photon emission computed tomography;   Procedure: computed tomography
7 Recruiting Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy
Condition: Malignant Mesothelioma
Interventions: Drug: pemetrexed disodium;   Other: clinical observation
8 Recruiting Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
Conditions: Malignant Mesothelioma;   Pulmonary Complications
Interventions: Genetic: microarray analysis;   Genetic: protein expression analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis
9 Recruiting Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
Condition: Malignant Peritoneal Mesothelioma
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
10 Recruiting Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy
Condition: Malignant Pleural Mesothelioma
Interventions: Biological: WT-1-vaccine Montanide + GM-CSF;   Biological: Montanide adjuvant + GM-CSF
11 Recruiting Amatuximab for High Mesothelin Cancers
Conditions: Carcinoma, Pancreatic Ductal;   Mesothelioma;   Ovarian Neoplasms;   Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Amatuximab (MORab-009)
12 Recruiting Treating Cancer With Anti-mesothelin Modified Lymphocytes
Conditions: Metastatic Cancer;   Pancreatic Cancer;   Mesothelioma
Interventions: Drug: Fludarabine;   Drug: Cycolphosphamide;   Biological: Aldesleukin
13 Recruiting Intrapleural Gene Transfer for Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Biological: SCH 721015
14 Recruiting Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Conditions: Thoracic Malignancy;   Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma
Intervention:
15 Recruiting Mithramycin for Lung, Esophagus, and Other Chest Cancers
Conditions: Lung Cancer;   Esophageal Cancer;   Mesothelioma;   Gastrointestinal Neoplasms;   Breast Cancer
Intervention: Drug: Mithramycin
16 Unknown † Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura
Conditions: Lung Cancer;   Metastatic Cancer
Interventions: Drug: chemotherapy;   Drug: porfimer sodium;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: spectroscopy;   Procedure: therapeutic conventional surgery
17 Recruiting Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Metastatic Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Procedure: quality-of-life assessment
18 Recruiting Collecting Tumor Samples From Patients With Gynecological Tumors
Condition: Cancer
Intervention: Other: biologic sample preservation procedure
To Top

† Indicates status has not been verified in more than two years